Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29509617 | 0.97 | OPRD1 (0.58) | OPRD1OPRM1 | |
| SCHEMBL29462069 | 0.95 | OPRD1 (0.65) | OPRD1OPRM1 | |
| SCHEMBL29509580 | 0.94 | OPRD1 (0.59) | OPRD1OPRM1 | |
| SCHEMBL5058350 | 0.89 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL5611736 | 0.89 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL30444236 | 0.86 | SLC6A2 (0.62) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL29706375 | 0.86 | OPRD1 (0.52) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL28184395 | 0.86 | OPRD1 (0.52) | OPRD1OPRM1 | |
| SCHEMBL21581709 | 0.85 | OPRM1 (0.58) | OPRD1OPRM1 | |
| SCHEMBL26454172 | 0.85 | OPRM1 (0.58) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126235-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Vanda Pharmaceuticals Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115335122-A | Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 | 万带兰制药公司 | 2022-11-11 | — | — | CN | claimed |
| EP-4722725-A2 | COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12441790-B2 | Binding proteins to the human thrombin receptor, PAR4 | MONASH UNIVERSITY (AU) | 2025-10-14 | — | — | US | disclosed |
| US-20250189545-A1 | COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| CN-116041341-B | Quinazoline PAR4 antagonist and medical application thereof | 中国药科大学 | 2025-02-28 | — | — | CN | disclosed |
| EP-4512469-A2 | BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4 | Monash University (AU) | 2025-02-26 | — | — | EP | disclosed |
| US-12235278-B2 | Compositions and methods for evaluation of antiplatelet drug sensitivity | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-118638794-B | Double-stranded siRNA, shRNA, pharmaceutical composition for regulating protease activated receptor 4 gene expression and application | 中国药科大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-3681911-B1 | BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4 | UNIV MONASH (AU) | 2024-11-27 | — | — | EP | disclosed |
| CN-118638794-A | Double-stranded siRNA, shRNA, pharmaceutical composition for regulating protease activated receptor 4 gene expression and application | 中国药科大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-115335122-A | Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 | 万带兰制药公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-111440146-B | Benzotriazine compound with PAR4 antagonistic activity and application thereof | 中国药科大学 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022213896-A1 | QUINOXALINE COMPOUND, PREPARATION METHOD, AND PHARMACEUTICAL APPLICATION THEREOF | 中国药科大学 | 2022-10-13 | — | — | WO | disclosed |
| EP-2277050-B2 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS | MOMENTA PHARMACEUTICALS INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-113150005-B | Quinoxaline compound, preparation method and application thereof in medicine | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-112074522-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112074523-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | disclosed |